1-11 of 11
Pamela A. Trail
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1073: A tumor-targeted CD40 agonistic DARPin® molecule leading to antitumor activity with limited systemic toxicity

Nicolo Rigamonti, Sarah Jetzer, Niels Van der Velden, Omar Abdelmotaleb, Sophie Barsin, Jonas Schwestermann, Susanne Mangold, Yvonne Kaufmann, Ralph Bessey, Andrea Valeri, Heidi Poulet, Christof Zitt, Pamela A. Trail, Victor Levitsky, Niina Veitonmäki, Clara Metz
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1073.
DOI: https://doi.org/10.1158/1538-7445.AM2020-1073
Published: 15 August 2020
View article
Journal Articles

Dual IGF-I/II–Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth

Jin Gao, Jon W. Chesebrough, Susan A. Cartlidge, Sally-Ann Ricketts, Leonard Incognito, Margaret Veldman-Jones, David C. Blakey, Mohammad Tabrizi, Bahija Jallal, Pamela A. Trail, Steven Coats, Klaus Bosslet, Yong S. Chang
Journal: Cancer Research
Cancer Res (2011) 71 (3): 1029–1040.
DOI: https://doi.org/10.1158/0008-5472.CAN-10-2274
Published: 01 February 2011
View article
PDF
Includes: Supplementary data
Journal Articles

2-Cyanopyridines as novel VEGFR-2 / VEGFR-3 inhibitors. Part 2. Inhibition of tumor growth and metastasis by a cyanopyridine

Lila Adnane, William J. Scott, Paul Adams, Volkhart Li, Scott M. Wilhelm, Gloria Hofilena, Marina Ichetovkin, Lori Lantz, Andrew Lyga, Dean Wilkie, Stephen Noell, Yichen Cao, Wendy Lee, Brian Raudenbush, Christopher Carter, Pamela A. Trail, Cathy Bull
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 886–887.
Published: 15 April 2006
View article
Journal Articles

BAY 43-9006 (Sorafenib) inhibits ectopic (s.c.) and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis

Yong S. Chang, Arris Henderson, Dahai Xue, Charles Chen, Angela McNabola, Dean Wilkie, Bruce Rowley, Christopher A. Carter, Bernd Riedl, Pamela A. Trail, Scott Wilhelm
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1372.
Published: 01 May 2005
View article
Journal Articles

BAY 43-9006 (Sorafenib) is a potent inhibitor of FLT3 tyrosine kinase signaling and proliferation in AML cells

Daniel Auclair, Donna Miller, Christopher Carter, Yong Chang, Barbara Polony, Xiaomei Zhang, Victoria Yatsula, Walter Pickett, Timothy Housley, Amy Burd, Hong Shi, Sandy Rocks, Richard Gedrich, Laura Abriola, Don Apanovitch, Istvan Enyedy, Jacques Dumas, Bernd Riedl, Pamela A. Trail, Scott M. Wilhelm
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1409.
Published: 01 May 2005
View article
Journal Articles

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang, Dean Wilkie, Angela McNabola, Hong Rong, Charles Chen, Xiaomei Zhang, Patrick Vincent, Mark McHugh, Yichen Cao, Jaleel Shujath, Susan Gawlak, Deepa Eveleigh, Bruce Rowley, Li Liu, Lila Adnane, Mark Lynch, Daniel Auclair, Ian Taylor, Rich Gedrich, Andrei Voznesensky, Bernd Riedl, Leonard E. Post, Gideon Bollag, Pamela A. Trail
Journal: Cancer Research
Cancer Res (2004) 64 (19): 7099–7109.
DOI: https://doi.org/10.1158/0008-5472.CAN-04-1443
Published: 01 October 2004
View article
PDF
Journal Articles

Inhibition of Angiogenesis and Metastasis in Two Murine Models by the Matrix Metalloproteinase Inhibitor, BMS-275291

Joseph G. Naglich, Maria Jure-Kunkel, Elora Gupta, Joseph Fargnoli, Arris J. Henderson, Anne C. Lewin, Randy Talbott, Andy Baxter, John Bird, Ranjev Savopoulos, Ruth Wills, Robert A. Kramer, Pamela A. Trail
Journal: Cancer Research
Cancer Res (2001) 61 (23): 8480–8485.
Published: 01 December 2001
View article
PDF
Journal Articles

Antitumor Activity of Carcinoma-reactive BR96-Doxorubicin Conjugate against Human Carcinomas in Athymic Mice and Rats and Syngeneic Rat Carcinomas in Immunocompetent Rats

Hans Olov Sjögren, M. Isaksson, David Willner, Ingegerd Hellström, Karl Erik Hellström, Pamela A. Trail
Journal: Cancer Research
Cancer Res (1997) 57 (20): 4530–4536.
Published: 01 October 1997
View article
PDF
Journal Articles

Effect of Linker Variation on the Stability, Potency, and Efficacy of Carcinoma-reactive BR64-Doxorubicin Immunoconjugates

Pamela A. Trail, David Willner, Jay Knipe, Arris J. Henderson, Shirley J. Lasch, Mary E. Zoeckler, Mark D. TrailSmith, Terrence W. Doyle, H. Dalton King, Anna Maria Casazza, Gary R. Braslawsky, Joseph Brown, Sandra J. Hofstead, Robert S. Greenfield, Raymond A. Firestone, Kathleen Mosure, Kathleen F. Kadow, Michael B. Yang, Karl Erik Hellström, Ingegerd Hellström
Journal: Cancer Research
Cancer Res (1997) 57 (1): 100–105.
Published: 01 January 1997
View article
PDF
Journal Articles

BR96 sFv-PE40, a Potent Single-Chain Immunotoxin That Selectively Kills Carcinoma Cells

Paula N. Friedman, Stephen J. McAndrew, Susan L. Gawlak, Dana Chace, Pamela A. Trail, Joseph P. Brown, Clay B. Siegall
Journal: Cancer Research
Cancer Res (1993) 53 (2): 334–339.
Published: 01 January 1993
View article
PDF
Journal Articles

Antigen-specific Activity of Carcinoma-reactive BR64-Doxorubicin Conjugates Evaluated in Vitro and in Human Tumor Xenograft Models

Pamela A. Trail, David Willner, Shirley J. Lasch, Aris J. Henderson, Robert S. Greenfield, Dalton King, Mary E. Zoeckler, Gary R. Braslawsky
Journal: Cancer Research
Cancer Res (1992) 52 (20): 5693–5700.
Published: 01 October 1992
View article
PDF